A study published recently in the AACR’s journal Cancer Discovery addresses the burgeoning question of the utility of high-throughput...
Last week, a flurry of U.S. Food and Drug Administration (FDA) oncology approvals concluded with the approval of the...
Earlier this week, the U.S. Food and Drug Administration approved the molecularly targeted therapeutic ribociclib (Kisqali) for use in...
Last week, the U.S. Food and Drug Administration (FDA) added a new therapeutic to the armamentarium for oncologists treating...
The U.S. Food and Drug Administration (FDA) recently approved the use of molecularly targeted therapeutic afatinib (Gilotrif) for treating...
Data presented at the AACR Annual Meeting 2016, on April 19, showed that a microdevice about the size of...
Last week, the U.S. Food and Drug Administration (FDA) announced that it had approved the use of crizotinib (Xalkori)...
The rapid fire of U.S. Food and Drug Administration (FDA) approvals of new anticancer therapeutics continued last week when...
Last week, the U.S. Food and Drug Administration (FDA) approved the use of cobimetinib (Cotellic) in combination with vemurafenib...
Levi Garraway, MD, PhD, co-chair of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston Nov....